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Abstract
Background: Rectal administration of artemisinin derivatives has potential for early treatment for
severe malaria in remote settings where injectable antimalarial therapy may not be feasible.
Preparations available include artesunate, artemisinin, artemether and dihydroartemisinin.
However each may have different pharmacokinetic properties and more information is needed to
determine optimal dose and comparative efficacy with each another and with conventional
parenteral treatments for severe malaria.
Methods: Individual patient data from 1167 patients in 15 clinical trials of rectal artemisinin
derivative therapy (artesunate, artemisinin and artemether) were pooled in order to compare the
rapidity of clearance of Plasmodium falciparum parasitaemia and the incidence of reported adverse
events with each treatment. Data from patients who received comparator treatment (parenteral
artemisinin derivative or quinine) were also included. Primary endpoints included percentage
reductions in parasitaemia at 12 and 24 hours. A parasite reduction of >90% at 24 hours was
defined as parasitological success.
Results: Artemisinin and artesunate treatment cleared parasites more rapidly than parenteral
quinine during the first 24 hours of treatment. A single higher dose of rectal artesunate treatment
was five times more likely to achieve >90% parasite reductions at 24 hours than were multiple
lower doses of rectal artesunate, or a single lower dose administration of rectal artemether.
Conclusion: Artemisinin and artesunate suppositories rapidly eliminate parasites and appear to
be safe. There are less data on artemether and dihydroartemisinin suppositories. The more rapid
parasite clearance of single high-dose regimens suggests that achieving immediate high drug
concentrations may be the optimal strategy.
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Background
In 1985, the Journal of Traditional Chinese Medicine
described the satisfactory efficacy of qinghaosu supposito-
ries in 100 patients with P. falciparum malaria, 4 of whom
had cerebral malaria [1]. Qinghaosu (artemisinin) deriva-
tives were soon recognised as having powerful antimalar-
ial activity [2] and a variety of formulations have since
been developed[3]. The efficacy and safety of oral and
parenteral artemisinin derivatives have been widely stud-
ied for both uncomplicated and severe malaria [4-7] and
these drugs form the basis of current antimalarial treat-
ment policy in most countries in the world [8].
During the past 10 years, the WHO has directed the devel-
opment of the highly active artemisinin derivative, artesu-
nate, to assess its value in settings where it might be given
rectally as a substitute for injectable treatment. The ration-
ale for the development was that, without effective treat-
ment, P. falciparum malaria can progress to severe malaria
and death within a matter of hours. The artemisinin deriv-
atives have been shown to have potent activity against
early trophozoite forms and to rapidly reduce heavy para-
site infections[3]. Therefore it was postulated that when
given as a suppository in areas where patients cannot
immediately access injectable therapy, they might confer
therapeutic advantages in preventing parasite develop-
ment to the more pathological stages that cause organ
complications in severe malaria [9]. Rectal preparations
have the advantage of being easy to administer in rural
areas; therefore it is anticipated that rectal administration
of an artemisinin derivative in remote settings might "buy
time" by halting or slowing the progress of disease while
a patient is being transported to a health-care facility
equipped to provide definitive treatment. Their utility
would consequently be greatest in areas where access to
injectable therapy is poor or does not exist. The clinical
evidence accumulated in the initial phase of this develop-
ment focused on measures of parasite reduction – a well-
established indicator of clinical effect in the evaluation of
antimalarial drugs.
In addition to artesunate, other artemisinin derivatives
formulated for rectal administration now include artem-
isinin, dihydroartemisinin and artemether. The available
published results suggest that all achieve a rapid, consist-
ent clinical response in regions where studies have been
undertaken, despite considerable inter-individual phar-
macokinetic variability[10-14]. However the different
artemisinin derivatives have different physicochemical
properties in adminstration; consequently some prepara-
tions might be more rapidly absorbed than others
[11,13,15-18]. Most clinical trials have employed small
sample sizes and none have directly compared the efficacy
of the different rectally administered artemisinin deriva-
tives with one another. In addition, substantial heteroge-
neity exists with respect to the dosing schedules
employed. There is therefore considerable uncertainty
regarding the optimal preparation and dosing schedules
to use.
Given the different aims, design, location, patient demo-
graphics and disease severity of clinical trials, we review
individual patient data from several trials to establish
whether there are significant differences in efficacy and
safety of different artemisinin-based suppositories in the
first 24 hours post treatment. More specifically we evalu-
ate: i) the efficacy of rectal artemisinins in comparison
with conventional treatments for severe malaria (includ-
ing parenteral quinine and parenteral artemisinins); ii)
the comparative efficacy of different artemisinin deriva-
tives for rectal use (namely, artesunate vs artemisinin vs
artemether); iii) the efficacy of different dosing regimens
(single vs multiple dosing) and total dose administered;
iv) the overall safety profile of rectally administered
artemisinins and differences between different drugs and
regimens.
Methods
Search strategy and selection criteria
Electronic searches of the National Library of Medicine's
MEDLINE database, Current Contents database and man-
ual searches of selected specialty journals were performed
to identify all the pertinent literature. MEDLINE database
engines (Ovid, PubMed and GratefulMed) were used with
the keywords "rectal", "artemisinin", and "treatment".
The search was further refined with the words "artesu-
nate", "artemether", "artemisinin", "dihydroartemisinin",
"suppositories", and "rectocaps" from 1980 to March
2006. Reference lists from qualitative topic reviews and
published clinical trials in English were also searched. We
attempted to obtain the original individual patient data
from all studies, regardless of publication status.
Selection criteria for inclusion of studies were clinical tri-
als that assessed the efficacy of a rectal artemisinin-based
preparation where individual patient data (inclusion/
exclusion criteria, age, parasitological status at baseline
and parasitology post treatment) were available. Compar-
ative and non-comparative studies were included, regard-
less of study design, geographical area, patient age group,
disease severity or the artemisinin derivative used. Safety
data and information on dosage was specifically
requested from the individual study investigators if this
was not provided or evident from a publication. Data
extraction was conducted by two investigators (MP, IR)
for efficacy data and two investigators (MW, MG) for
safety.BMC Infectious Diseases 2008, 8:39 http://www.biomedcentral.com/1471-2334/8/39
Page 3 of 13
(page number not for citation purposes)
Efficacy endpoints
The main focus of the review was on the assessment of
parasite reduction and clinical response of patients during
the first 24 hours following treatment. This was consid-
ered most appropriate, given the intended indication as
emergency pre-referral treatment, where ameliorating dis-
ease progression within 24 hours, i.e. while the patient is
being transported to a clinic or hospital, is likely to be
most important.
All efficacy definitions used are consistent with the scien-
tific literature. Parasite reduction ratio (PRR) at 12 and 24
hours was assessed as the percent reduction of parasitae-
mia at 12 and 24 hours from baseline parasitaemia. Para-
sitological success was defined as the absence of clinical
deterioration from baseline and a PRR at 24 hours of ≥
90%. In the analysis (see further below) both the contin-
uous variable PRR and the binary variable of ≥ 90% para-
site reduction were used, the former to define efficacy at
12 hours, and the latter to define efficacy at 24 hours.
Because definitions of parasite and fever clearance times
differed from study to study, these time-to-event variables
were re-derived from the serial parasite density estima-
tions and temperatures for individual patients. Parasite
clearance and fever clearance time were defined as the
time at which the first negative blood smear or normal
temperature (<37.5°C axillary or <38.0°C oral) was
recorded. The effect of consolidation treatment on recru-
descence of the infection during follow-up was evaluated
from baseline to the reappearance of parasitaemia.
Safety endpoints
Except in two trials, laboratory markers of safety (includ-
ing haematological and biochemical indices) were not
available. Safety analyses were consequently restricted to
clinical descriptions of reported adverse events. In the
absence of prospective standardised methods for defining,
assessing, reporting and classifying adverse events across
all trials, and due to inherent difficulties in clinically dis-
tinguishing drug side-effects from manifestations of
malarial infection, principal investigators who contrib-
uted data were asked to re-review individual patient data
retrospectively and reassess all reported adverse events.
Ideally this was performed directly from case record forms
where archived data were accessible. Each reported event
was thus re-classified by the clinical investigator as being
either "unlikely", "possibly", "probably" or "definitely"
due to the treatment. Those events considered possibly,
probably or definitely drug-related were thereafter re-clas-
sified as "potentially drug-related" for the purposes of the
pooled analysis.
Statistical analysis
Original data from different studies were merged into a
master data set. In the analysis mainly hierarchical models
were used, with treatment arm as the second level of clus-
tering. In some cases within-study comparisons of differ-
ent treatment arms was possible and methods for meta-
analysis were then accordingly applied in the analysis of
PRR. A hierarchical mixed model applying the DerSimo-
nian & Laird method was used with the estimate of heter-
ogeneity being taken from the inverse variance fixed-effect
model [19].
Most of the analyses, however, were based on compari-
sons of treatment arms from different studies, here called
pooled analyses, and conducted as follows: For PRR, lin-
ear mixed effect models with random intercepts were
applied. In the analysis at 12 hours, an identity link (nor-
mal distribution) was used. At 24 hours a large proportion
of the PRR values for the artemisinins were close to 100%
at 24 hours, and these were then categorised into binary
observations (PRR >90% versus <90%). A logistic link was
then used in the analysis. It should be noted that crude
mean values of PRR at 24 hours using the identity link are
also given for description. We systematically examined the
effect (stepwise backward elimination of covariates not
reaching a significance level of p = 0.05) of the following
covariates within all analyses: baseline parasitaemia, age,
region, total treatment dose provided within the initial 12
and 24 hours, and severity of disease as defined by the
evaluating clinician.
Time-to-event analyses, including time to parasite and
fever clearance and the efficacy of the consolidated treat-
ment in suppressing parasitaemia post treatment (reap-
pearance of parasites), were represented using crude
Kaplan-Meier plots (these are provided as graphs only
where the difference in estimates was significant). Hazard-
ratios were estimated using a non-hierarchical Cox regres-
sion model applying the same stepwise backward elimi-
nation of covariates as above. Intra-rectal treatments were
compared to parenteral treatment when followed by the
same consolidation treatment in one analysis and intra-
rectal treatments followed by different consolidation
treatments were compared in a second analysis. Time to
parasite clearance, age, region, disease severity, parasitae-
mia at 72 hours (often the start of consolidation treat-
ment) were assessed as covariates through stepwise
backward elimination of covariates.
All statistical computations were performed with Stata for
Windows (version 8 and 9.2, Stata Corporation, College
Station, Texas-USA).BMC Infectious Diseases 2008, 8:39 http://www.biomedcentral.com/1471-2334/8/39
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Results
Studies included
A total of 27 studies were identified in patients using the
search criteria; 4 studies were in healthy normal volun-
teers [11,15,16,18]. Twelve studies were not included in
the analysis: 5 trials were on pharmacokinetics – 8 to 15
patients per trial, total of 59 patients [14,17,20-22] with
no efficacy data available. This left 7 trials, 242 patients
with uncomplicated malaria[23-26] and 185 patients
with severe and complicated malaria treated with rectal
artemisinins[23,27-29] that were not available to be
included in our analyses.
Individual patient data were available from 15 clinical tri-
als (Table 1). There were 4 randomised, controlled, clini-
cal trials with parenteral quinine as comparator:
Molyneux1997–8 [30], Barnes1998 [30], Phuong1992–5
[31], Aceng2002–3 [32], and 6 trials in which the compa-
rator was another artemisinin given parenterally or orally
in moderately severe, hyperparasitaemic and severe
patients: Krishna1996 [10], Looareesuwan1996 (unpub-
lished), VanVugt1997–9 (unpublished), Vinh 1997–9
[33], Hien1998 (unpublished), Karunajeewa2003–4 [34].
The remaining trials used a different dosage or treatment
regimen with the same artemisinin-based rectal prepara-
tion as a comparator: Looareesuwan1995 [35],
Looareesuwan2000 (unpublished), Than1998 (unpub-
lished). There were 2 non- comparative trials –
Bhatt1994–5 [36], Karunajeewa2001 [37]. We were pro-
vided with an additional 10 individual patient observa-
tions not included in one published trial (Phuong1992–
5) [31] which completed with fewer patients than
planned due to recruitment difficulties, but where the
team continued to collect clinical descriptions of severe
malaria in children, using rectal artemisinins which the
hospital preferred to quinine. The data from these 10
cases were added to the pooled analyses.
Altogether the studies included in this analysis enrolled a
total of 1167 patients in 37 separate treatment arms. Five
patients who simultaneously received rectal artesunate
and quinine were excluded, leaving a total of 1162
patients included in the analysis. Of these 786 had been
treated with rectal administration of an artemisinin deriv-
ative and 376 with a comparator drug which was either a
parenteral artemisinin (236) oral artesunate (17) or
parenteral quinine (123). The majority of included
patients treated with a rectal artemisinin were from main-
land South East Asia (487) or Papua New Guinea (89),
with relatively fewer patients from Africa (210). Thirty-
one percent of patients were children under 5, 11.8% chil-
dren aged 6–10, 21.3% adolescents aged 11–20 years and
36% adults over 20 years of age. Treatment exposure
information is provided in Table 2.
Efficacy
1 comparisons with quinine
Two studies (Molyneux1997–8 and Barnes1998) contrib-
uted to a standard meta analysis as both studies compared
clinical and parasitological response of artesunate 10 mg/
kg versus quinine 10 mg/kg. The log-transformed PRR at
24 h with a single dose of rectal artesunate was signifi-
cantly better than quinine, weighted mean difference 0.60
(95% CI 0.32–0.89, p ≤ 0.0001). The pooled analyses
showed that the artemisinin derivatives, regardless of
route of administration and number of doses, were supe-
rior to quinine in reducing parasitaemia at 12 and 24
hours (Figure 1 and Table 3). In the model, parasitological
efficacy was partly dependent on age and severity of dis-
ease but independent of baseline parasitaemia and region
of use.
Time to clearance of parasitaemia for the different drugs
are given in Figure 1. Multiple Cox regression analysis
showed a significant difference in time to clearance
between parenteral artemisinins and parenteral quinine
(Hazard Ratio HR = 4.1; p ≤ 0.0001), between single dose
rectal artesunate and parenteral quinine (HR = 2.7; p ≤
0.0001) and between single dose artemisinin supposito-
ries and quinine (HR = 2.4;p = 0.03) with parasitaemia at
baseline being a significant covariate in the parenteral
comparison (HR = 0.99; p ≤ 0.0001) and in the compari-
son with single dose artesunate (HR = 0.99; p = 0.042),
but not in the comparison with single dose artemisinin
suppository treatment.
2 Comparisons between artemisinin derivatives
Mixed model estimates comparing efficacy of the different
artemisinin derivatives are provided in Table 4.
2.1 Parenteral versus rectal administration
Parenteral artesunate or artemether versus single-dose artemisinin 
or artesunate rectal administration
Mean PRR using either a single dose artesunate or single
dose artemisinin was higher than parenteral artemisinins
at 12 hours (65.9% for rectal treatment compared with
60.0% for parenteral treatment). This was observed also
in the adjusted model presented in Table 4, in which
severe disease was an important covariate in response
prior to 12 hours. At 24 hours the difference was in the
same direction, with 90.0% reduction in parasitaemia
with rectal artemisinins compared with 83.8% parasite
reduction with parenteral artemisinins. The proportion
PRR>90 at 24 hours gave an OR = 1.75 (p = 0.072) in
favour of rectal administration. However, the Kaplan
Meier survival plot provided in Figure 2 demonstrates the
overall superiority of parenteral administration beyond
the 24-hour period (unadjusted log rank test of survival
function p ≤ 0.0001 for a single dose of rectal artesunate/
artemisinin versus parenteral treatment). Baseline parasiteBMC Infectious Diseases 2008, 8:39 http://www.biomedcentral.com/1471-2334/8/39
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Table 1: Studies for which individual patient data was provided, by study, treatment and number of patients
Region Country Study 
Identification* 
[Ref]
Treatment Group Number of Patients Studied Total Number of 
Patients
Moderately Severe Severe Uncomplicated
Africa Ghana Krishna 1996 [10] Artesunate ir, single 
dose
23 23
Artemisinins** 
parenteral
11 11
Kenya Bhatt 1994–5 [36] Artesunate ir, multiple 
dose
23 23
Malawi Molyneux 1997–8 
[30]
Artesunate ir, single 
dose
86 86
Quinine parenteral 22 22
South Africa Barnes 1998 [30] Artesunate ir, single 
dose
27 27
Quinine parenteral 8 6 14
Quinine parenteral+ 
Artesunate ir
55
Uganda Aceng 2002–3 [32] Artemether ir, single 
dose
51 51
Quinine parenteral 52 52
Total Number of Patients – Africa 177 137 314
Asia- Oceania Myanmar Than 1998 Artesunate ir, multiple 
dose
100 100
Papua New Guinea Karunajeewa 2001 
[37]
Artesunate ir, multiple 
dose
48 48
Papua New Guinea Karunajeewa 2003–4 
[34]
Artesunate ir, multiple 
dose
41 41
Artemisinins 
parenteral
38 38
Thailand Looareesuwan 1996 Artesunate ir, single 
dose
26 26
Artemisinins 
parenteral
24 24
Thailand Van Vugt 1997–9 Artesunate ir, single 
dose
44 44
Artesunate po 17 17
Thailand Looareesuwan 1995 
[35]
Artesunate ir, multiple 
dose
60 60
Thailand Looareesuwan 2000 Artesunate ir, single 
dose
69 69
Vietnam Phuong 1992–5 [31] Artemisinin, multiple 
dose
46 46
Artemisinins 
parenteral
40 40
Quinine parenteral 35 35
Vietnam Vinh 1992–4 [33] Artemisinin ir, 
multiple dose
52 52
Artemisinins 
parenteral
123 123
Vietnam Hien 1998 Artemisinin ir, single 
dose
46 46
Artesunate ir, single 
dose
44 44
Total Number of Patients – Asia 240 565 48 853
Grand Total 417 702 48 1167
* Study Identification: Investigator name and year of patient enrolment [References are included where available].
** Artemisinins parenteral: this consisted of Artemether or Artesunate administered via intra-muscular or intravenous routeBMC Infectious Diseases 2008, 8:39 http://www.biomedcentral.com/1471-2334/8/39
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count was a significant covariate (p ≤ 0.0001) in the Cox
regression giving an adjusted HR = 0.52 (p ≤ 0.0001) for
a single rectal treatment versus parenteral treatment.
2.2 Response between different derivatives given rectally
Multiple dose artesunate versus single dose artesunate
All multiple dose artesunate studies were undertaken in
Asia and regression analyses were limited to patients from
this region. The crude PRR at 12 hours with a multiple
dose was 52.6% compared to a single dose of rectal artesu-
nate at 64.1%. In the adjusted model (Table 4), the PRR at
12 hours was 32.7% with multiple dose treatment and
57.7% with single dose therapy, with severity of disease a
significant covariate (OR = 19.5, p = 0.011).
At 24 hours, the mean PRR was 87.5% for the multiple
dose treatment and 93.7% for the single dose. An adjusted
logistic regression model indicated that a patient with
moderately severe or severe disease had a five times
greater chance of achieving a 90% reduction of parasitae-
mia at 24 hours with single dose artesunate rectal treat-
ment (multiple dose compared with single OR = 0.19 (p
≤ 0.0001)), and that the total dose over 24 hours was the
only variable independently influencing this outcome
(Table 4). In all studies with multiple dose rectal admin-
istration with artesunate (all in Asia), a 200 mg supposi-
tory was provided sequentially at intervals over 72 hours,
resulting in a mean exposure of 7.9 mg/kg over 12 hours
and 14.9 mg/kg over 24 hours. Single dose studies
attempted to provide a dose as close to 10 mg/kg as possi-
ble at initiation of therapy; the mean dose was 8.5 mg/kg
over 24 hours (10.1 mg/kg in studies in Thailand).
The Kaplan-Meier analysis (log-rank test p = 0.45) and
Cox regression adjusted analysis indicated no significant
difference in the time to clearance of parasitaemia
between multiple and single dose rectal artesunate treat-
ment (HR = 1.04 p = 0.76), the assumption of propor-
tional hazards not being justified. However, parasitaemia
at baseline(HR = 0.99), total treatment dose prior to 12
hours (HR = 1.1), and patient age (HR = 0.64) were three
significant covariates in this analysis (all at p = 0.0001).
Single dose artemisinin versus single dose artesunate
Two Vietnamese studies with single dose artemisinin
given rectally over 24 hours were compared with single
dose artesunate studies in Asia. Mean PRRs at 12 hours
with single dose artemisinin and single dose artesunate
suppositories were 72.3% and 64.2%, respectively. Corre-
sponding PRRs at 24 hours were 95.5% and 93.9%,
respectively, with OR = 1.13 (p = 0.813). The Kaplan
Meier analysis (log-rank test p = 0.71) and Cox regression
analysis did not show a significant difference in time to
parasite clearance between the two treatments (HR = 1.07,
p = 0.73). The only covariate of significance was parasite
count at initiation of treatment (HR = 0.99, p = 0.023).
Multiple dose artemisinin versus single dose artemisinin
There were three studies in the comparison: one study
with single dose artemisinin over 24 hours and two stud-
ies with multiple dose artemisinin, all conducted in Viet-
nam. Mean PRR at 12 hours was 72.3% with single dose
artemisinin suppositories and 63.2% for multiple dose
artemisinin. No covariate, including total dose which was
significantly higher in the multiple dose group (20 mg/kg
versus 45 mg/kg, p ≤ 0.0001), influenced outcome in the
adjusted model at 12 hours. At 24 hours, the crude mean
values of PRR were 89.1% for multiple dose artemisinin
treatment and 95.5% for single dose treatment with an
OR = 0.60 p = 0.40. The Kaplan Meier survival analysis
Table 2: Summary of Age and Doses used in clinical trials by type of therapy(mg/kg)
Treatment group Median age, years (range) Dose(mg/kg) at Initiation of 
therapy (mean ± SD)
Total dose over first 12 
hours (mg/kg) (mean ± SD)
Total dose over first 24 
hours (mg/kg) (mean ± SD)
Artemether ir*, single dose 2.08 (0.42 – 5) 6.7 ± 1.19 6.7 ± 1.19 6.7 ± 1.19
Artemisinin ir, single dose 19 (4 – 41) 20.0 ± 0 20.0 ± 0 20.0 ± 0
Artemisinin ir, multiple 
dose
20 (0.7 – 62) 31.5 ± 8 45.1 ± 14 45.1 ± 14
Artesunate ir, multiple 
dose
19 (1.3 – 80) 6.65 ± 4 8.1 ± 4.17 14.8 ± 7.64
Artesunate ir, single dose – 
10 mg/kg
12 (1.33 – 58) 9.4 ± 2.47 9.4 ± 2.47 9.4 ± 2.53
Artesunate per os 6 (0.92 – 15) 4.0 ± 0 4.0 ± 0 4.0 ± 0
Artemisinins parenteral 18 (0.5 – 66) 2.94 ± 0.61 2.94 ± .0.6 3.43 ± 0.99
Quinine parenteral 3 (0.3 – 49) 17.6 ± 4.31 24.2 ± 4.96 36.6 ± 5.7
Quinine parenteral + 
Artesunate ir
45 (32 – 60) - - -
Artesunate ir, single – 20 
mg/kg
6.3 (2 – 30) 19.4 ± 1.63 19.4 ± 1.63 20.7 ± 0.99
* ir: Intra-rectalBMC Infectious Diseases 2008, 8:39 http://www.biomedcentral.com/1471-2334/8/39
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(log rank test p = 0.98) and the adjusted Cox regression
analysis of multiple versus single (HR = 1.24, p = 0.27)
did not indicate any difference in time to parasite clear-
ance between the two groups although parasite count at
baseline was a significant covariate (HR = 0.99, p = 0.05).
Patient weight data was not available to enable estimation
of the effect of dose (mg/kg).
Single dose artemether versus single dose artesunate
Only one study with artemether suppositories was per-
formed (Uganda), with a single rectal dose of artemether
being given once daily for 7 days. Mean PRR at 12 hours
was 53.5% for single dose rectal artemether compared
with 73.5% with single dose artesunate (p ≤ 0.0001). No
covariate influenced this outcome significantly. At 24
hours, mean PRR was 83.1% for single dose artemether
and 96.7% with single dose artesunate (p ≤ 0.0001). The
odds of achieving a 90% reduction in parasitaemia at 24
hours was about one fifth for artemether compared to
artesunate (OR = 0.22, p = 0.002) in a moderately severe
or severe patient. Mean total treatment dose during the
initial 24 hours with single dose artemether was 6.72 mg/
kg compared with 9.4 mg/kg with single dose artesunate.
The Kaplan Meier analysis (log-rank test p = 0.18) and
Cox regression analysis (HR = 1.56, p = 0.21) of time-to-
clearance of parasitaemia showed no significant differ-
ences between the two types of artemisinin-based suppos-
itories: artemether given once daily for 7 days versus
artesunate given only once in the first 24 hours and fol-
lowed by sulphadoxine-pyrimethamine (HR = 1.56, p =
0.21).
Effect of consolidation treatment on recrudescence
Consolidation treatment varied (Table 5). A multiple Cox
regression analysis of time-to-recrudescence gave a non-
significant difference between an intra-rectal and
parenteral artemisinin derivative when both were fol-
lowed by mefloquine (HR = 0.78, p = 0.639) but parasi-
taemia at 72 hours was a significant covariate in the
analysis (HR = 0.99, p = 0.003). However, in a compari-
son of intra-rectal treatment followed by sulphadoxine-
pyrimethamine (SP) versus intra-rectal treatment fol-
lowed by mefloquine, the Kaplan Meier analysis (log-rank
test p ≤ 0.0001) and Cox regression analysis (HR = 0.36, p
= 0.006) of time to recrudescence between the two treat-
ments showed a significant difference in favour of meflo-
quine, with parasitaemia at 72 hours (HR = 0.99, p =
0.005) and region of study (HR = 0.16, p = 0.001) being
significant covariates in the analysis (Figure 3).
Safety
A total of 196 adverse events were reported in 140
(17.8%) of the 786 patients treated with rectal artemisi-
nins (Table 6). By comparison 67 adverse events were
reported in 30 (24.3%) of 123 patients treated with
parenteral quinine.
Of the 196 adverse events in patients treated with suppos-
itories, 37 events in 21 patients were considered to be
potentially drug-related, based on classifications provided
by the clinical investigators. A further 105 events in 69
patients were classified as non-drug related and 50 events
in 54 patients could not be or were not assigned a cause.
Therefore, overall, 2.7% (21/786) of all rectal artemisinin-
treated patients were thought to have had a potentially
drug-related adverse event, 8.8%(69/786) a non-drug
related adverse event and an additional 6.4% (54/786)
had an adverse event of uncertain causality. By compari-
son, 27 of 67 (40.3%) reported adverse events occurring
in 123 quinine-treated patients were considered drug-
related meaning that 22.0% (27/123) of quinine-treated
patients experienced an adverse event that was considered
potentially drug-related.
Approximately 29.7% (11/37) of suspected drug-related
adverse events in rectal artemisinin-treated patients were
defined as affecting the body as a whole (including fever,
Cumulative probability of having parasites: parenteral quinine  versus treatment with artemisinins Figure 1
Cumulative probability of having parasites: parenteral quinine 
versus treatment with artemisinins.
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headache and unspecified pain), 2.7% (1/37) were related
to the nervous system (dizziness), 8.1% (3/37) were
related to the special senses (hearing impairment) and
48.6% (18/37) related to the gastrointestinal system
(vomiting, nausea, diarrhoea, constipation, abdominal
pain). For those in the quinine comparator group, 25.9%
(7/27) of adverse events were related to the nervous sys-
tem, 29.6% (8/27) to the digestive system, 18.5%(5/27)
affected special senses/hearing and 14.8% (4/27) the hae-
mopoetic system. A meaningful comparison of safety pro-
files between the different artemisinin products was
beyond the scope of this analysis. It should be noted that
most of the safety data presented here are from patients
treated with either artesunate (591) or artemisinin sup-
positories (144).
In summary, the total incidence of adverse events consid-
ered by clinicians to be possibly drug-related was esti-
mated at being between 2.7% and 9.0% of all rectal
artemisinin-treated patients, compared with 22% of qui-
Table 3: Parasite reduction ratio at 12 and 24 hours compared with quinine: mixed model results
12 hr final model 24 hr descriptive model** 24 hr final model
% p-value N % p-value N Odds Ratio p-value
Single dose Rectal Artemisinin vs Parenteral Quinine
Parenteral quinine 48.6 35 68.7 30
Rectal artemisinin 72.3 0.337 46 95.5 0.29 46 8.2* 0.000
Multiple dose Rectal Artesunate vs Parenteral Quinine
Parenteral Quinine 27.5 123 67.1 106
Multiple rectal artesunate 56.5 0.04 272 89 0.004 254 11.03 0.009
Multiple Rectal Artemisinin vs Parenteral Quinine
Parenteral Quinine 48.6 35 68.7 30
Multiple rectal artemisinin 63.3 0.343 98 89.1 0.090 80 3.70* 0.004
Single dose Rectal Artesunate vs Parenteral Quinine
Parenteral 36 293 63.7 106
Rectal 79 0.000 123 99 0.000 264 23.5 0.000
Age 5–14 yrs*** -12 0.043 -9.4 0.015 0.33 0.015
Age >14 yrs*** -18 0.026 -6.9 0.152 0.32 0.021
Severe disease 11.5 0.045
* No solution was found for the mixed model. Corresponding non-hierarchical regression used instead.
** Descriptive estimates of parasite reductions at 24 hours are provided only for comparisons with 12 hour estimates, see section 'Statistical 
analysis'
*** Reference category is <5 years
Table 4: Parasite reduction ratio at 12 and 24 hours: Mixed model results
12 hr final model 24 hour descriptive model** 24 hr final model
% p-value N % p-value N Odds Ratio p-value N
Single Rectal Artemisinin or Artesunate vs Parenteral Artemisinins
Parenteral 45.7 225 83.8 49 179
Rectal 59.1 0.018 339 90.0 0.069 331 1.75* 0.072 201
Severe malaria 16.6 0.008
Multiple Artesunate vs Single Artesunate
Single artesunate 57.7 169 93.7 80 155
Multiple artesunate 32.7 0.001 249 87.5 0.279 307 0.19 0.004 232
Total dose at 24 hours 19.5 0.011 1.14 0.008
Single Artemisinin vs Single Artesunate
Single artesunate 64.2* 169 93.9 46 46
Single artemisinin 72.3 0.262 46 95.5 0.792 155 1.13* 0.813 155
Multiple Artemisinin vs Single Artemisinin
Single artemisinin 72.3 46 95.5 80 80
Multiple artemisinin 63.2 0.545 98 89.1 0.348 46 0.60* 0.403 46
Single Artemether vs Single Artesunate
Single artesunate 73.5 51 96.7 109 109
Single artemether 53.5 0.000 124 83.1 0.000 41 0.22* 0.002 41
* No solution was found for the mixed model. Corresponding non-hierarchical regression used instead.
** Descriptive estimates of parasite reductions at 24 hours are provided only for comparisons with 12 hour estimates, see section 'Statistical 
analysis'BMC Infectious Diseases 2008, 8:39 http://www.biomedcentral.com/1471-2334/8/39
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nine-treated patients. The majority of possibly drug-
related adverse events in rectal artemisinin-treated
patients involved either the gastrointestinal system or
were generalized and non-specific in nature and were not
severe.
Discussion
This review addresses the lack of any data directly compar-
ing the therapeutic efficacy and safety of the different rec-
tal preparations of artemisinin derivatives. The pooled
analysis of individual patient data suggest that artemisi-
nin and artesunate suppositories rapidly eliminate para-
sites and are safe. There is far less evidence for artemether
[32] and no studies of dihydroartemisinin suppositories
were available to be included in this analysis. The results
indicate that both artemisinin and artesunate, whether as
single or multiple dose regimens, induce a superior para-
sitological response than parenteral quinine over the 24
hours following initiation of treatment. Regimens
employing a higher single dose of rectal artesunate were
five times as likely to result in >90% parasite reductions at
24 hours than were multiple lower doses of rectal artesu-
nate or than a single administration of artemether. These
results imply that dosage regimens that result in immedi-
ate high blood concentrations of drug [10,30,34,38] are
those best able to reduce parasitaemia in patients with
evolving severe malaria and that sustained drug exposure
achieved by sequential treatment with moderate doses
[20,21,35,39] offers no therapeutic advantage.
The analysis used the rate of parasite clearance in the first
24 hours following treatment as the primary endpoint to
compare therapeutic efficacy of alternative drugs and reg-
imens. This endpoint has been commonly used in studies
of antimalarial efficacy, particularly for treatments
intended for severe malaria [40]. Parasite clearance is a
surrogate marker of clinical response but it cannot be
assumed that superior parasite clearance equates with
improved clinical outcome and lower mortality. Although
parenteral artemisinin derivatives have long been recog-
nised as having superior parasite clearance to quinine, it
remained uncertain until recently whether this character-
istic converted into a survival benefit. A recent trial com-
paring iv artesunate with parenteral quinine
demonstrated a 30% lower mortality with artesunate,
confirming that more rapid initial parasite clearance may
translate to reduced mortality in severe adult malaria [41].
Therefore, although the current pooled analysis was not
powered to assess mortality as an endpoint, the differ-
ences in parasite clearance rates between rectal artemisi-
nins and parenteral quinine, and between different rectal
artemisinin dosing regimens, should be regarded as
important indicators of possible real differences in thera-
peutic efficacy and clinical benefit. It should also be noted
that any future study designed to use mortality as an end-
Cumulative probability of having parasites: parenteral artem- isinins versus rectal artemisinins Figure 2
Cumulative probability of having parasites: parenteral artem-
isinins versus rectal artemisinins.
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Cumulative probability of recrudescing with consolidation 
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point to compare different rectal artemisinins (or to dem-
onstrate non-inferiority of a rectal artemisinin with a
parenteral preparation such as iv artesunate) would
require such a large sample size that it is unlikely ever to
be implemented. Therefore the surrogate marker of para-
site clearance used in this analysis is likely to remain the
best available evidence on which to base comparisons of
treatment efficacy for the rectal artemisinins.
Table 5: Consolidation treatment used in different clinical studies
Initial Treatment group Consolidation Treatment Follow-up period Study Identification/Year of 
Enrolment (Ref)
Total patients
Artemether ir*, single dose Artemether ir 7 days Aceng 2002–3 [32] 51
Artemisinin ir, single dose Mefloquine + SP 72 hours Hien 1998 46
Artemisinin ir, multiple dose Mefloquine None post discharge Phuong 1992–5 [31] 46
Vinh 1992–4 [33] 52
Artesunate ir, multiple dose Artesunate + SP 72 hours Karunajeewa 2003–4 [34] 41
Mefloquine 28 days Looareesuwan 1995 [35] 60
Than 1998 100
None post discharge Bhatt 1994–5 [36] 23
Chloroquine or SP None post discharge Karunajeewa 2001 [37] 48
Artesunate ir, single dose Artesunate + Mefloquine 28–42 days Van Vugt 1997–9 44
28 days Looareesuwan 2000 69
Mefloquine 28 days Looareesuwan 1996 26
Chloroquine or SP 30 days Krishna 1996 [10] 23
SP 28–42 days Molyneux 1997–8 [30] 113
Mefloquine-SP 72 hours Hien 1998 44
Artesunate per os Artesunate + Mefloquine 28–42 days Van Vugt 1997–9 17
Artemisinins parenteral Artesunate + SP 72 hours Karunajeewa 2003–4 [34] 38
Mefloquine 28 days Looareesuwan 1996 24
None post discharge Phuong 1992–5 [31] 40
Vinh 1992–4 [33] 123
Chloroquine or SP 30 days Krishna 1996 [10] 11
Quinine parenteral Quinine 7 days Aceng 2002–3 [32] 52
SP 28–42 days Barnes 1998 [30] 36
None post discharge Phuong 1992–5 [31] 35
Quinine parenteral + Artesunate ir SP 42 days Barnes 1998 [30] 5
Grand Total 1167
* ir: Intra-rectal
Table 6: Adverse events noted in patients treated with suppositories and parenteral treatment, by treatment group.
Rectal artemisinin Non-rectal artemisinin 
comparator
Non-artemisinin comparator 
(quinine)
TOTAL
Total no. patients included in analysis 786 253 123 1162
Total no. (%) of patients in whom one or 
more adverse event reported
140 (18) 24 (9) 30 (24) 194
Total no. of adverse events: 196 43 67 306
Classification (aetiology):
Possibly drug-related 37 14 27 78
Not likely to be drug related 105 28 40 173
Unable to be classified 54 1 0 55
Classification of possibly drug-related 
events according to body system:
Generalised 11 1 0 12
Neurological 1 1 7 9
Digestive 18 10 8 36
Urogenital 1 1 0 2
Haemopoetic 3 1 4 8
Special senses (hearing) 3 0 5 8
Other 0 0 3 3BMC Infectious Diseases 2008, 8:39 http://www.biomedcentral.com/1471-2334/8/39
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There has been a recent systematic review of published
data on rectal artemisinin derivatives with a focus on
pharmacokinetics of various preparations and a summary
of efficacy[42]; however there were less data and limited
capacity to standardize definitions and account for statis-
tical heterogeneity. In contrast, the current meta-analysis
synthesizes individual patient data from studies meeting
well-defined inclusion criteria and for whom standard-
ized end-points were calculated. The analysis has enabled
a robust and statistically powerful comparison of efficacy
outcomes between rectal artemisinins, parenterally
administered artemisinins and parenteral quinine that
has had the capacity to examine and allow for the influ-
ence of covariates such as age, geographic origin and dis-
ease severity. Given that only a small number of direct
comparative trials have been performed, this meta-analy-
sis of 1162 individual patients represents a significant
contribution to the available comparative efficacy data on
rectal artemisinins. In particular, its results showing that
early parasite clearance of rectal artemisinins is clearly
superior to that of quinine, and appears equivalent to that
of parenteral artemisinins is an important observation,
given the results of the recent SEQUAMAT trial[41].
There are methodological limitations inherent in making
comparisons of safety across several trials and in attribut-
ing causality to adverse events in patients with malaria.
Overall the data suggest that the artemisinin based sup-
positories studied have a benign safety profile, consistent
with that of the artemisinins in general[43,44]. There were
no special concerns related specifically to the rectal route
of administration and there were no reports suggestive of
serious neurotoxicity. Neurotoxicity of the artemisinin
derivatives has been described in animals but this now
appears to be associated with sustained exposure to the
central nervous system rather than peak levels [45]. There-
fore a single dose as pre-referral treatment (rather than
multiple dosing) may also have additional theoretical
benefits in terms of safety as well as efficacy. Pharmacoki-
netic data have largely been derived from studies of
artesunate[10,20,21,30,31,38,47] and artemisinin[14-
18,48,49] with little data on rectal formulations of arte-
mether[32] or dihydroartemisinin[22]. In the absence of
sufficient pharmacokinetic information it cannot be
assumed that all rectal preparations have the same efficacy
or safety profile. Well-designed clinical trials that directly
compare the efficacy, safety and pharmacokinetic profile
of the different suppository formulations are needed.
The evidence from this analysis supports the WHO recom-
mendation for the use of artesunate and artemisinin as
initial pre-referral treatment[8]. The analysis was not
designed to assess long-term cure rates and there are insuf-
ficient data on which to substantiate the use of rectal treat-
ment for full management of severe malaria.
Conclusion
Early effective treatment with artemisinin based supposi-
tories has potential as a lifesaving intervention, particu-
larly at the periphery of the health-care system, where
suppositories might be administered early in lieu of
parenteral treatment in remote communities by relatively
untrained personnel. Combined with accurate diagnosis
and artemisinin combination therapy, rectal artemisinins
have been effectively used to reduce malaria incidence
and mortality in Asia [3,50,51], an approach which holds
great promise for malaria control elsewhere.
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